PE20141149A1 - Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) - Google Patents

Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Info

Publication number: PE20141149A1
Authority: PE; Peru
Prior art keywords: tissue factor; tfpi; monoclonal antibodies; antibodies against; path inhibitor
Prior art date: 2011-04-01

Application number

PE2013002137A

Other languages

English (en)

Spanish (es)

Inventor

Zhuozhi Wang

John Murphy

Tobias Marquardt

Dieter Moosmayer

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-01

Filing date

2012-03-30

Publication date

2014-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141149(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-03-30 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2014-08-28 Publication of PE20141149A1 publication Critical patent/PE20141149A1/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PE2013002137A 2011-04-01 2012-03-30 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) PE20141149A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161471101P	2011-04-01	2011-04-01

Publications (1)

Publication Number	Publication Date
PE20141149A1 true PE20141149A1 (es)	2014-08-28

Family

ID=46932389

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2013002137A PE20141149A1 (es)	2011-04-01	2012-03-30	Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Country Status (37)

Country	Link
US (5)	US20140294832A1 (2)
EP (1)	EP2694544B1 (2)
JP (4)	JP6170903B2 (2)
KR (2)	KR20190079698A (2)
CN (2)	CN107090046A (2)
AU (3)	AU2012236296A1 (2)
BR (1)	BR112013025376A2 (2)
CA (2)	CA3068997A1 (2)
CL (1)	CL2013002811A1 (2)
CO (1)	CO6890074A2 (2)
CR (1)	CR20130499A (2)
CU (1)	CU20130128A7 (2)
CY (1)	CY1121538T1 (2)
DK (1)	DK2694544T3 (2)
DO (1)	DOP2013000218A (2)
EA (2)	EA201991704A3 (2)
EC (1)	ECSP13012913A (2)
ES (1)	ES2722824T3 (2)
GT (1)	GT201300229A (2)
HK (1)	HK1243426A1 (2)
HR (1)	HRP20190467T1 (2)
HU (1)	HUE042706T2 (2)
IL (4)	IL228633B (2)
LT (1)	LT2694544T (2)
MX (1)	MX2013011218A (2)
MY (2)	MY190951A (2)
PE (1)	PE20141149A1 (2)
PH (4)	PH12013502039B1 (2)
PL (1)	PL2694544T3 (2)
PT (1)	PT2694544T (2)
RS (1)	RS58633B1 (2)
SG (2)	SG10201602606UA (2)
SI (1)	SI2694544T1 (2)
TR (1)	TR201905101T4 (2)
UA (1)	UA113623C2 (2)
WO (1)	WO2012135671A2 (2)
ZA (1)	ZA201308169B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2747721C (en)	2008-12-19	2021-07-20	Baxter International Inc.	Tfpi inhibitors and methods of use
CN102325795B (zh) †	2008-12-22	2015-03-25	诺沃—诺迪斯克有限公司	针对组织因子途径抑制剂的抗体
RS59830B1 (sr)	2010-03-01	2020-02-28	Bayer Healthcare Llc	Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
EP2547355B1 (en)	2010-03-19	2017-01-11	Baxalta GmbH	Tfpi inhibitors and methods of use
CN107090046A (zh) *	2011-04-01	2017-08-25	拜尔健康护理有限责任公司	针对组织因子途径抑制物(tfpi)的单克隆抗体
EP2827883B1 (en) *	2012-03-21	2019-05-08	Baxalta GmbH	Tfpi inhibitors and methods of use
SG11201406129QA (en) *	2012-03-30	2014-10-30	Bayer Healthcare Llc	Protease-regulated antibodies
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
ES2926773T3 (es) *	2013-03-15	2022-10-28	Novo Nordisk As	Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
US20160009818A1 (en)	2013-03-15	2016-01-14	Bayer Healthcare Llc	Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics
JP6584397B2 (ja) *	2013-07-19	2019-10-02	ノヴォノルディスクアー／エス	凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
CN106687482B (zh) *	2014-09-17	2022-01-25	诺和诺德股份有限公司	能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
EP4279128A3 (en)	2015-02-25	2024-02-28	Mogam Institute for Biomedical Research	Novel antibody binding to tfpi and composition comprising the same
IL302353A (en) *	2015-08-19	2023-06-01	Pfizer	TFPI inhibitory antibodies and their uses
CN112424593A (zh) *	2018-07-25	2021-02-26	索尼公司	凝血系统分析装置
CN112442127A (zh) *	2019-08-29	2021-03-05	苏州康宁杰瑞生物科技有限公司	针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06153985A (ja) *	1992-11-16	1994-06-03	Teijin Ltd	モノクローナル抗体
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CN102325795B (zh) *	2008-12-22	2015-03-25	诺沃—诺迪斯克有限公司	针对组织因子途径抑制剂的抗体
RS59830B1 (sr) *	2010-03-01	2020-02-28	Bayer Healthcare Llc	Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
CN107090046A (zh) *	2011-04-01	2017-08-25	拜尔健康护理有限责任公司	针对组织因子途径抑制物(tfpi)的单克隆抗体
US8613919B1 (en) *	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
US9592297B2 (en) *	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations

2012
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/en active
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en not_active Ceased
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Ceased
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko not_active Expired - Fee Related
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039B1/en unknown
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
2019
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown

Also Published As

Publication number	Publication date
IL274686A (en)	2020-06-30
BR112013025376A2 (pt)	2017-07-25
KR20140019428A (ko)	2014-02-14
GT201300229A (es)	2014-11-13
PH12013502039A1 (en)	2013-12-16
PL2694544T3 (pl)	2019-07-31
RS58633B1 (sr)	2019-05-31
MY165499A (en)	2018-03-27
EP2694544A2 (en)	2014-02-12
JP2018172411A (ja)	2018-11-08
IL228633B (en)	2018-03-29
AU2012236296A1 (en)	2013-10-24
CY1121538T1 (el)	2020-05-29
JP2017113019A (ja)	2017-06-29
PH12019500441A1 (en)	2020-10-12
NZ615969A (en)	2016-01-29
CR20130499A (es)	2013-10-24
EA201301107A1 (ru)	2014-11-28
WO2012135671A3 (en)	2012-12-13
WO2012135671A2 (en)	2012-10-04
US20190194353A1 (en)	2019-06-27
CA2831907A1 (en)	2012-10-04
JP6363747B2 (ja)	2018-07-25
HRP20190467T1 (hr)	2019-05-03
ZA201308169B (en)	2016-03-30
EP2694544B1 (en)	2019-01-23
IL283829A (en)	2021-07-29
MX2013011218A (es)	2013-10-17
CN107090046A (zh)	2017-08-25
KR101995302B1 (ko)	2019-07-02
IL257145A (en)	2018-03-29
JP6170903B2 (ja)	2017-07-26
SG193594A1 (en)	2013-10-30
EA201991704A2 (ru)	2020-03-31
KR20190079698A (ko)	2019-07-05
SG10201602606UA (en)	2016-04-28
CN103797030A (zh)	2014-05-14
CA2831907C (en)	2020-03-24
PH12013502039B1 (en)	2013-12-16
DOP2013000218A (es)	2013-11-15
DK2694544T3 (en)	2019-04-15
HK1243426A1 (zh)	2018-07-13
JP2021019619A (ja)	2021-02-18
HUE042706T2 (hu)	2019-07-29
JP2014511685A (ja)	2014-05-19
ES2722824T3 (es)	2019-08-19
AU2019201814A1 (en)	2019-04-04
CA3068997A1 (en)	2012-10-04
IL228633A0 (en)	2013-12-31
EA034214B1 (ru)	2020-01-17
EP2694544A4 (en)	2015-03-25
EA201991704A3 (ru)	2020-06-30
US20220041752A1 (en)	2022-02-10
PH12019500439A1 (en)	2020-10-12
SI2694544T1 (sl)	2019-06-28
LT2694544T (lt)	2019-04-25
US20140294832A1 (en)	2014-10-02
UA113623C2 (uk)	2017-02-27
US20170107298A1 (en)	2017-04-20
CL2013002811A1 (es)	2014-02-28
PT2694544T (pt)	2019-04-02
CN103797030B (zh)	2017-05-31
US20180194857A1 (en)	2018-07-12
IL274686B (en)	2021-09-30
MY190951A (en)	2022-05-24
PH12019500440A1 (en)	2020-10-12
TR201905101T4 (tr)	2019-05-21
CU20130128A7 (es)	2014-03-26
ECSP13012913A (es)	2014-02-28
CO6890074A2 (es)	2014-03-10
AU2017203105A1 (en)	2017-06-01

Legal Events

Date	Code	Title	Description
2018-07-16	FG	Grant, registration

Publication	Publication Date	Title
CL2019002056A1 (es)	2019-11-29	Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
EA201791168A1 (ru)	2017-09-29	Способы и составы для лечения сосудистых заболеваний глаз
PE20190907A1 (es)	2019-06-26	Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
PE20141166A1 (es)	2014-09-16	Anticuerpos anti-angptl3 y usos de los mismos
EP2582722A4 (en)	2013-12-18	ANTIBODIES AGAINST GD2
MX2023004333A (es)	2023-05-04	Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
AR080026A1 (es)	2012-03-07	Metodos de tratamiento de enfermedades autoinmunitarias con antagonistas del ligando 4 similar a delta (dll4)
MX2018008658A (es)	2021-10-19	Composiciones y metodos para inhibir masp-1 y/o masp-2 y/ o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
EA201690159A1 (ru)	2016-05-31	Способы и композиции для лечения рака
UY34116A (es)	2013-01-03	El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
PE20250415A1 (es)	2025-02-14	Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos
UA118029C2 (uk)	2018-11-12	Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201491644A1 (ru)	2014-12-30	Фармацевтические композиции
MX2017001011A (es)	2018-05-28	Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
MX2017006323A (es)	2017-08-21	Anticuerpos que comprenden regiones constantes pesadas modificadas.
PE20160538A1 (es)	2016-05-19	Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi)
MY166776A (en)	2018-07-23	Humanised anti-ctla4 antibodies
CO6390041A2 (es)	2012-02-29	Agentes y antagonistas fijaodres de notch y metodos para el uso de los mismos.
CO6300826A2 (es)	2011-07-21	Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CO6950476A2 (es)	2014-05-20	Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
DOP2013000218A (es)	2013-11-15	Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
AR102595A1 (es)	2017-03-08	Anticuerpos anti-ang2 y métodos de utilización
EE05760B1 (et)	2016-03-15	Ravimkoostis
AR084627A1 (es)	2013-05-29	Formulacion farmaceutica que comprende una droga biofarmaceutica
CY1126032T1 (el)	2023-11-15	Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap